Table 3. Gefitinib, steady-state CSF and plasma concentrations, and clinical outcomes.

Patient	Gefitinib dose (mg)	Pretreatment EGFR genotype	Steady-state gefitinib concentra tion, CSF (nM)	Steady-state gefitinib concentration, plasma (nM)	Clinical improve ment	CSF cytology clearance	Radiological improve ment	CNS progression-free survival (months)	Survival (months)
1	750	Exon 19 deletion	14.7 – 17.1	1362.8 – 1835.4	Yes	Partial	No	2.7	3.9
2	750	Not done	48.8 – 54.0	1345.9	Yes	No	No	1.9	1.9
3	750	L858R	41.5	4993.0	No	No	No	1.6	1.6
4	1000	Exon 19 deletion	57.5	5094.4	No	No	No	1.0	1.6
5	1000	Exon 19 deletion	93.6 – 143.1	4090.5	Yes	Partial	No	2.7	3.5
6	1000	Exon 19 deletion	17.3 – 21.6	1552.3 – 1599.6	Yes	Yes	No	2.3	5.1
7	1000	Exon 19 deletion	21.3 – 21.8	2105 – 2935.9	No	No	No	4.0	4.0